医学
指南
重症监护医学
临床试验
药物治疗
肺动脉高压
临床实习
疾病
血管阻力
梅德林
肺动脉压
药品
血压
内科学
内皮素受体拮抗剂
持续性肺动脉高压
循证医学
联合疗法
内皮素受体
治疗方法
心脏病学
作者
Danya Z. Jafri,James M. Beck,Samantha A. Kaplan,Allegra Keeler,Bryan Sanchez,Daniela Brady,William H. Frishman,Wilbert S. Aronow,Avi Levine,Erika B. Rosenzweig,Gregg M. Lanier
标识
DOI:10.1097/crd.0000000000001239
摘要
Pediatric pulmonary arterial hypertension (PAH) is a relentless and potentially fatal disease marked by elevated pulmonary vascular resistance and pulmonary pressure as a result of unchecked vascular remodeling, proliferation, and dysfunction. While pharmacological treatment algorithms for adult PAH are well-established and frequently updated, pediatric PAH treatment guidelines in the United States are generally based on limited clinical trials and expert opinion, leaving clinicians to extrapolate from adult data and expert consensus rather than pediatric-specific, evidence-based protocols. Endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin-pathway agents remain the therapeutic cornerstone, yet clinical practice is being reshaped by pivotal therapeutic developments. Recent advances highlight differences in monotherapy versus combination pharmacological regimens, alongside active trials investigating interventional/surgical procedures in the amelioration of long-term outcomes. This review seeks to consolidate contemporary data and clinical trial highlights to reflect a necessary shift toward precise, developmentally informed pharmacotherapy in children, underscoring the pressing need for an updated pharmacological guideline that incorporates pediatric-specific trials and harmonizes labeling and long-term safety surveillance in the treatment of pediatric PAH.
科研通智能强力驱动
Strongly Powered by AbleSci AI